Apr 14, 2023 / 12:00PM GMT
Operator
Good morning. My name is [Rob], and I will be your conference operator today. At this time, I would like to welcome everyone to the Ocugen investor and analyst event. (Operator Instructions) Please note that today's conference call is being recorded. Tiffany Hamilton, Head of Communications, you may begin your conference.
Tiffany Hamilton - Ocugen - Head of Communications
Thank you so much, [Rob]. Earlier this morning, we issued a press release announcing positive preliminary safety and efficacy results from our Phase 1/2 trial of OCU400, a modifier gene therapy product for the treatment of retinitis pigmentosa and Leber congenital amaurosis. We encourage listeners to review the press release which is available on our website at ocugen.com. This call is being recorded and a replay with the accompanying slide presentation will be available on the investor section of the Ocugen website for approximately 45 days.
This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are
Ocugen Inc To Host Virtual Investor & Analyst Event Transcript
Apr 14, 2023
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers